Wagner, Patrick
Levine, Edward A.
Kim, Alex C.
Shen, Perry
Fleming, Nicole D.
Westin, Shannon N.
Berry, Laurel K.
Karakousis, Giorgos C.
Tanyi, Janos L.
Olson, Madeline T.
Madajewski, Brian
Ostrander, Brian
Krishnan, Kartik
Balch, Charles M.
Bartlett, David L.
Funding for this research was provided by:
OncoNano Medicine
Cancer Prevention and Research Institute of Texas
Article History
Received: 4 December 2023
Accepted: 25 February 2024
First Online: 15 April 2024
Disclosure
: Dr. Shannon Westin received grants/contracts to institution from Astra Zeneca, AvengeBio, Bayer, Bio-Path, Clovis Oncology, GSK, Jazz Pharmaceuticals, Mereo, Novartis, Nuvectis, Roche/Genentech, and Zentalis and consulted for AstraZeneca, Caris, Clovis Oncology, Eisai, EQRX, Gilead, GSK, Immunocore, ImmunoGen, Lilly, Merck, Mereo, Mersana, NGM Bio, Nuvectis, Roche/Genentech, SeaGen, Verastem, Vincerx, Zentalis, and ZielBio; Dr. Giorgos Karakousis received research support from industry to fund clinical trial at institution; Mr. Brian Madajewski is the holder of intellectual property in the form of patents and copyrights (Hall K.A.; Madajewski B; Kaplan H; “pH Responsive Compositions, Formulations, and Methods of Imaging a Tumor” 2020, United States patent appl.62/937141, 18 November 2020); Dr. Charles Balch is the chair of the Scientific Advisory Board of OncoNano Medicine and invested in OncoNano stock; and Dr. David Bartlett was responsible for the clinical trial patient enrollment fee being negotiated between AHN and OncoNano. The authors acknowledge support from the Cancer Research and Prevention Institute of Texas, OncoNano Medicine.